Jehan Rowlands, PharmD

Jehan Rowlands is a seasoned and experienced regulatory strategist whose career spans over twenty years at companies including Forest, Sanofi, Otsuka, NPS, InfaCare, Actinium, and Rafael. He has worked closely with the FDA to develop and execute regulatory strategies for drug candidates for a wide range of therapeutic indications. Throughout his career, he has contributed to the development of innovative products for unmet medical needs leading to the filing and approval of Namenda, Natpara, and accelerating development and early NDA filing of stannsoporfin for neonatal hyperbilirubinemia while at InfaCare. Jehan most recently joins us from Rafael Pharmaceutical where he was Vice President, Head of Regulatory Affairs.

Jehan received his B.S. in Pharmacy as well as a Doctor of Pharmacy (Pharm.D.) degree from Rutgers University, Ernest Mario School of Pharmacy.  He also completed a post-doctoral pharmaceutical industry fellowship jointly sponsored by Rutgers University and Hoffmann-La Roche.

Jonathan Lanfear, MBA

President and Chief Executive Officer, Jonathan Lanfear, is an accomplished biopharmaceutical executive with more than 25 years of experience in the life sciences industry and has demonstrated distinct success in creating and driving strategies, building and developing teams, establishing R&D partnerships, and creating new business opportunities. Prior to joining HiberCell, Jonathan was a Principal at Lanfear Advisors LLC, where he provided Corporate Strategy and Operations consultancy services to public and private sector biotech and bio/pharmaceutical companies.  Prior to establishing his consulting practice in 2020, he was the Global Head of R&D Business Development at Takeda Pharmaceuticals, based in Cambridge MA.

Before joining Takeda in 2011, Jonathan spent approximately eight years at Pfizer Inc as a Senior Director and Transactions Lead in the Worldwide Business Development, Strategy, & Innovation (WWBDS&I) organization based in New York.  His prior roles also include Biotechnology Equity Research at AG Edwards/Wachovia and Team Leader, GMP Operations and Downstream Processing at Searle/Pharmacia (prior to the company’s acquisition by Pfizer).  Over his career, Jonathan has led hundreds of transactions of all types, integrated acquired entities, lead operations, and managed strategic alliances/partnerships.  He holds a Bachelor’s degree in Chemical Engineering and a Master’s degree in Bioengineering, both from the University of Michigan (Ann Arbor), along with an MBA from Washington University (St. Louis).  Jonathan is also a member of the Board of Directors of Molecular Templates, an oncology focused, publicly traded company based in New Jersey.

Tom Chittenden, Ph.D., DPhil, PStat

Dr. Tom Chittenden is Chief Technology Officer for HiberCell and is responsible for global AI/ML R&D.

Tom is an Omega Society Fellow and an Accredited Professional Statistician™ with the American Statistical Association. He holds faculty appointments at Boston Children’s Hospital and the Harvard Medical School. His research has been published in top-tier scientific journals, including featured articles in Nature and Science.  In 2019, Forbes named him among the top 100 AI Pioneers in Drug Discovery and Advanced Healthcare. In 2021, he was named the Business Intelligence Group (BIG) AI Excellence Award Winner. Tom was also the recipient of the 2021 Global Genius Directory Award in recognition of his contribution to cognitive science and artificial intelligence.  Tom is regarded as one of the world’s leading authorities on AI and causal statistical machine learning in the biomedical sciences.

Tom holds a Ph.D. in Molecular Cell Biology and Biotechnology from Virginia Tech and a DPhil in Computational Statistics from the University of Oxford. His multidisciplinary postdoctoral training includes experimental investigations in Molecular and Cellular Cardiology from the Dartmouth Medical School; Biostatistics and Computational Biology from the Dana‐Farber Cancer Institute and the Harvard School of Public Health; and Computational Statistics, Statistical Methodology, and Statistical Machine Learning from the University of Oxford.

Patricia Oliver, Ph.D.

Patricia Oliver, Ph.D., is a pharmaceutical veteran nearly three decades of experience encompassing all aspects of CMC. A proven leader at driving CMC activities, Patricia has led the strategic and operational management of CMC teams to produce targeted therapeutics in compliance with the highest quality assurance/regulatory standards. She has authorized dozens of regulatory documents (INDs, IMPDs, NDAs, ANDAs) and has successfully managed the development of both small molecule and biologics drug candidates from lead optimization to commercialization. She has helped bring to market Ritonavir®, Kaletra®, Telaprevir® and Glatopa® and has multiple papers and patents reflecting her contributions to these and many other drug candidates.

Patricia received her Ph.D. in organic chemistry from the University of Wisconsin-Madison and her bachelor’s degree in chemistry/pre-medicine from the College of the Holy Cross.

Joseph Talamo, CPA

Joe Talamo is chief financial officer at HiberCell. He has more than 25 years of biotechnology industry experience in publicly-traded, development and commercial stage companies with expertise in capital fund raising activities and merger and acquisition transactions. Prior to joining HiberCell, Joe served as the chief financial officer of Caladrius Biosciences, Inc., where he led initiatives to raise over $150 million to fund the company’s operations, including numerous private and public offerings, and the divestiture of its contract manufacturing subsidiary.  Joe also held various senior financial positions at OSI Pharmaceuticals, Inc., which was acquired by Astellas in 2010, most recently serving as its vice president and corporate controller where he helped build the accounting and finance infrastructure to support the clinical development and commercial launch of Tarceva®.  Joe began his career at KPMG in the Health Care and Life Sciences Audit Group, and currently serves as treasurer of the Cura Foundation, a public charity dedicated to raising awareness about adult stem cells and their therapeutic promise.

Joe received a B.B.A in accounting and an MBA in finance from Hofstra University. He is a certified public accountant in the State of New York.

Michele Gargano, MS.c.

Michele Gargano, MS.c., has almost 30 years of industry experience in early-stage to BLA/NDA drug development. She brings extensive leadership experience having held positions of increasing responsibility throughout her career. Prior to joining HiberCell, Michele was the vice president of clinical development and program management at Biothera Pharmaceuticals, Inc., where she was responsible for managing clinical operations, cross-functional programming and regulatory affairs for multiple development programs. She has been responsible for 14 INDs for the treatment of cancer, various gastrointestinal, hepatic, and ophthalmic indications, and cystic fibrosis working closely with FDA’s CDER and CDRH divisions and select global health authorities. She has authored numerous clinical documents and regulatory submissions including clinical protocols, meeting briefing packages, breakthrough therapy and orphan drug applications, and has managed collaborative/ licensing relations furthering development.

Michele holds a B.A. in cultural anthropology and government from Sweet Briar College, and a general certificate and M.Sc. in social anthropology from the London School of Economics.

Nandita Bose, Ph.D.

Nandita Bose, Ph.D., has more than 15 years experience in the immuno-oncology field. She joined HiberCell from Biothera Pharmaceuticals, Inc., where she served as senior vice president of translational immunology. She has extensive experience in translational research involving delineation of immunopharmacodynamic effects in healthy volunteers and cancer patients as part of Phase I/II/III company-sponsored trials and investigator-initiated trials/ compassionate-use studies.

In addition to being adjunct faculty at North Dakota State University, she has held leadership roles in several scientific organizations. As the only industry member of the Education Committee of American Association of Immunologists (AAI), she has chaired committee-sponsored symposia to mentor undergrads and post-doctoral fellows. She is a working member of the Industry Council of Society for Immunotherapy of Cancer (SITC) and has sat on scientific grant review committees for the American Association for Cancer Research (AACR). She is a reviewer for several cancer immunology journals including SITC’s leading journal, Journal for Immunotherapy of Cancer (JITC).

Nandita earned her Ph.D. in biomedical sciences from the University of Georgia and conducted her postdoctoral work in cellular immunology at University of Minnesota and 3M Pharmaceuticals.

David Surguladze, M.D.

David Surguladze, M.D., has more than 22 years of industry experience in preclinical drug discovery and development. He has extensive leadership experience having held positions of increasing responsibility throughout his career. Prior to joining HiberCell, David served as Director of Preclinical Pharmacology at Eli Lilly and Company, where he was responsible for preclinical evaluation of a diversified portfolio of novel cancer therapeutics that included small molecules, biologics, and ADCs. Additionally, he provided support for translational biomarker identification and patient tailoring strategies working closely with members of other multidisciplinary teams, as well as utilizing external resources through CROs. As a senior scientist at Nobex Corporation, he guided preclinical drug development efforts from target identification through IND submission for multiple programs in the areas of inflammation, diabetes and CNS disorders. During David’s scientific career, his efforts have led to 15 IND submissions and 2 marketed therapies for cancer – Cyramza and Portrazza. He has authored multiple peer-reviewed publications, a book chapter, and several patents.

David is a certified general surgeon and earned his M.D. in Georgia from Tbilisi State Medical University.

Ari Nowacek, M.D., Ph.D.

Ari Nowacek, M.D, Ph.D., is a Principal with ARCH Venture Partners. Dr. Nowacek focuses on identifying/evaluating new life science technologies, forming new companies, and provides operational assistance to early-stage portfolio companies. Dr. Nowacek is a physician-scientist by training with publications in the areas of neuroscience, virology, and antiretroviral therapeutic development. His research has led to 3 issued and 2 pending patents for therapeutic and R&D applications.

Ari holds a B.S. in Biology and a B.S. in Psychology from the University of Indiana-Bloomington where he graduated Magna Cum Laude and was elected to Phi Beta Kappa. He also holds an M.D. and Ph.D. from the University of Nebraska Medical Center and an M.B.A. from the University of Nebraska-Omaha. He subsequently completed a medical residency in pathology and post-doctoral research at The University of Chicago, Harvard Medical Schools and Massachusetts General Hospital.

Mark J. Mulvihill, Ph.D.

Mark is a passionate and seasoned drug hunter with an entrepreneurial spirit and intense desire to transform patient’s lives through the discovery and translation of breakthrough medicines. With more than two decades of small molecule drug discovery and development experience, Mark has a proven track record, having advanced numerous early cancer programs from a continuum of innovative discovery ideas (DNA-encoded libraries, natural products, small molecule-mediated protein-protein interactions, SBDD). Importantly, Mark has led these efforts from proof of concept/tool chemistry through to development/clinical candidate designation. During his career, Mark has held roles of increasing scientific and leadership responsibility, across a multitude of therapeutic areas in large pharma as well as the biotech sector. He has successfully led programs from the bench as a chemistry leader. This success provided additional opportunities for leadership growth with Mark transitioning to a global project leader, a senior project advisor and department head of chemistry at OSI/Astellas Pharmaceuticals. Armed with his 12 years of experience at OSI/Astellas, Mark transitioned to X-Rx, Inc. a startup company focused on the rapid progression of DNA-encoded library hits to partnered development candidates in a fully virtual outsourcing model. As the senior vice president of chemistry and CMC, Mark led two DNA-encoded library hits that were progressed through IND-enabling studies and out licensing. With a desire to return to his discovery roots, Mark accepted a position with Warp Drive Bio as the vice president of chemistry where he led chemistry and drug discovery efforts for the small molecule assisted receptor targeting, SMARTTM platform, as well as the natural product genome to molecules platform. During his tenure at Warp, Mark successfully led a team responsible for the generation of lead molecules against several critical oncology targets previously considered undruggable. Collectively, his leadership efforts have resulted in the identification and advancement of numerous development/clinical candidates across a variety of disease areas most notably, Lisitinib, OSI-027, X-022 and X-165.

Mark holds a B.S. in chemistry from Millsaps College, where he was awarded a Howard Hughes fellowship and performed research under the guidance of Dr. R. A. Berry. Mark then went on to earn his Ph.D. in synthetic organic chemistry from the University of Notre Dame under the mentorship and guidance of Professor Marvin J. Miller. Mark has a combination of over 100 publications, in the form of patents and applications thereof as an inventor and peer-reviewed journal articles as an author.